sur TuHURA Biosciences, Inc.
Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial
TuHURA Biosciences, Inc. and Kintara Therapeutics, Inc. announced that Kineta Inc. has reopened enrollment for the VISTA-101 clinical trial. This trial evaluates the efficacy of KVA12123 in patients with advanced solid tumor cancer.
To date, 30 out of a projected 39 patients have been enrolled. The trial includes monotherapy and combination arms utilizing KVA12123 with Merck's KEYTRUDA® (pembrolizumab). Completion of enrollment is anticipated by the end of 2024.
Initial results show KVA12123 has a favorable safety profile with no dose-limiting toxicities. Partial response and stable disease were observed in combination cohorts, while monotherapy cohorts showed durable stable disease. Further data was presented at the AACR Annual Meeting 2024.
The trial's progress is a crucial milestone, supported by a $5 million nonrefundable payment from TuHURA to Kineta. Both companies are collaborating closely on the study during TuHURA's due diligence period for the potential acquisition of KVA12123 assets.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de TuHURA Biosciences, Inc.